TY - JOUR
T1 - Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy
AU - Quintás-Cardama, Alfonso
AU - Kantarjian, Hagop
AU - O'Brien, Susan
AU - Jabbour, Elias
AU - Borthakur, Gautam
AU - Ravandi, Farhad
AU - Verstovsek, Srdan
AU - Shan, Jianqin
AU - Cortes, Jorge
PY - 2011/6
Y1 - 2011/6
N2 - We investigated the impact of carrying more than one BCRABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8%) of 92 patients carrying mutations had more than one mutation: 4 (4%) in chronic phase, 2 (2%) in accelerated phase, and one (1%) in blast phase. The cytogenetic response rate to second generation TKIs for patients with no, one, or more than one mutation was 88%, 69%, 50% (P=0.03) in chronic phase, 54%, 42%, 50% in accelerated phase (P=0.67), and 35%, 25%, 0% (P=0.63) in blast phase, respectively. No differences were observed in event free survival or overall survival in accelerated or blast phase according to their mutational status. However, the 4-year event free survival rates among patients in chronic phase with no, one, or more than one BCR-ABL1 mutation were 56%, 49%, and 0%, respectively (P=0.02), with overall survival rates of 91%, 69%, and 75%, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation.
AB - We investigated the impact of carrying more than one BCRABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8%) of 92 patients carrying mutations had more than one mutation: 4 (4%) in chronic phase, 2 (2%) in accelerated phase, and one (1%) in blast phase. The cytogenetic response rate to second generation TKIs for patients with no, one, or more than one mutation was 88%, 69%, 50% (P=0.03) in chronic phase, 54%, 42%, 50% in accelerated phase (P=0.67), and 35%, 25%, 0% (P=0.63) in blast phase, respectively. No differences were observed in event free survival or overall survival in accelerated or blast phase according to their mutational status. However, the 4-year event free survival rates among patients in chronic phase with no, one, or more than one BCR-ABL1 mutation were 56%, 49%, and 0%, respectively (P=0.02), with overall survival rates of 91%, 69%, and 75%, respectively (P=0.13). In conclusion, patients with more than one BCR-ABL1 mutation fare worse than those with no or one mutation.
KW - ABL1 mutation
KW - CML
KW - Multiple mutations
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=79958056962&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958056962&partnerID=8YFLogxK
U2 - 10.3324/haematol.2010.039321
DO - 10.3324/haematol.2010.039321
M3 - Article
C2 - 21357704
AN - SCOPUS:79958056962
SN - 0390-6078
VL - 96
SP - 918
EP - 921
JO - Haematologica
JF - Haematologica
IS - 6
ER -